BMC Cancer

CORRECTION | Open Access

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

Yoon-La Choi[1,2†], Ensel Oh[3,4†], Sarah Park[5], Yeonju Kim[6], Yeon-Hee Park[7], Kyug Song[3], Eun Yoon Cho[2], Yun-Chul Hong[8], Jong Sun Choi[9], Jeong Eon Lee[10], Jung Han Kim[10], Seok Jin Nam[10], Young-Hyuck Lim[7], Jung-Hyun Yang[10], Young Kee Shin[3,4*]

Correction

After the publication of this work [1], we found that there were some mistakes in calculating the percentage of composition in Table 1 (1). Clinicopathologic characteristics of breast cancer subtypes. We are therefore providing the revised Table 1, with the updated data for rows 'Mucinous carcinoma', 'Metaplastic carcinoma' and 'Others'. In the sub-content of Table 1, 'Histological type', the total

Table 1. Clinicopathologic characteristics of breast cancer subtypes

Variables	All N=951 No.	All (%)	IHC-Luminal A N=486 51.1% No.	(%)	IHC-Luminal B N=123 12.9% No.	(%)	IHC-HER2 N=113 11.9% No.	(%)	IHC-BLBC N=139 14.6% No.	(%)	IHC-QNBC/5NP N=90 9.5% No.	(%)	IHC-TNBC N=229 24.1% No.	(%)	P value between five subtypes *,†	P value between four subtypes **,†
Age Group (years)															<0.001	<0.001
<50	590	62.0	297	61.1	87	70.7	51	45.1	97	69.8	58	64.4	155	67.7		
≥50	361	38.0	189	38.9	36	29.3	62	54.9	42	30.2	32	35.6	74	32.3		
Family history of breast cancer															0.006	0.086
No	916	96.3	470	96.7	121	98.4	111	98.2	126	90.6	88	97.8	214	93.4		
Yes	35	3.7	16	3.3	2	1.6	2	1.8	13	9.4	2	2.2	15	6.6		
Tumor Size															0.014	0.006
≤ 2 cm	392	41.2	228	46.9	39	31.7	35	31.0	52	37.4	38	42.2	90	39.3		
2-5 cm	493	51.8	231	47.5	75	61.0	64	56.6	76	54.7	47	52.2	123	53.7		
> 5cm	66	6.9	27	5.6	9	7.3	14	12.4	11	7.9	5	5.6	16	7.0		
N Staging															0.178	0.014
N0	498	52.4	246	50.6	52	42.3	63	55.8	89	64.0	48	53.3	137	59.8		
N1	247	25.9	131	27.0	40	32.5	22	19.5	31	22.3	23	25.6	54	23.6		
N2	118	12.4	64	13.2	19	15.4	13	11.5	12	8.6	10	11.1	22	9.6		
N3	88	9.2	45	9.3	12	9.8	15	13.3	7	5.0	9	10.0	16	7.0		
AJCC stage															0.014	0.008
I	254	26.7	148	30.5	19	15.4	22	19.5	38	27.3	27	30.0	65	28.4		
II	467	49.1	221	45.5	69	56.1	57	5.04	78	56.1	42	46.7	120	52.4		
III	230	24.2	117	24.1	35	28.5	34	30.1	23	16.5	21	23.3	44	19.2		
LN involvement															0.016	0.020
Negative	498	52.4	246	50.6	52	42.3	63	55.8	89	64.0	48	53.3	137	59.8		
Positive	453	47.6	240	49.4	71	57.7	50	44.2	50	36.0	42	46.7	92	40.2		
Nuclear Grade															<0.001	<0.001
Low	92	9.7	67	13.8	5	4.1	3	2.7	9	6.5	8	8.8	17	7.4		
Intermediate	486	51.1	308	63.4	65	52.8	40	35.4	26	18.7	47	52.2	73	31.9		
High	373	39.2	111	22.8	53	43.1	70	61.9	104	74.8	35	38.9	139	60.7		
Histological Grade															<0.001	<0.001
Well	100	10.5	63	13.0	10	8.1	11	9.7	8	5.8	8	8.9	16	7.0		
Moderate	597	62.8	334	68.7	76	61.8	65	57.5	71	51.1	54	56.7	122	53.3		
Poor	254	26.7	89	18.3	37	30.1	37	32.7	60	43.2	31	34.4	91	39.7		
Estrogen Receptor (ER)															<0.001	<0.001
Negative	364	38.3	11	2.3	11	8.9	113	100.0	139	100.0	90	100.0	229	100.0		
Positive	587	61.7	475	97.7	112	91.1	0	0.0	0	0.0	0	0.0	0	0.0		

Figure 1

* Correspondence: ykeeshin@snu.ac.kr
† Contributed equally
[3]Research Institute of Pharmaceutical Science
Full list of author information is available at the end of the article

BioMed Central

number of 'Others' was corrected from 18 to 16, and the composition of 'Others' type was slightly changed according to breast cancer subtypes. For IHC-Her2 subtype, the number of 'Others' was changed from 4 to 3, and 6 cases which were previously unidentified were assigned to corresponding subtypes. One case to IHC-BLBC, 2 cases to IHC-QNBC/5NP and 3 cases to IHC-TNCB. There was no effect on statistical analysis with the correction.

Author details
[1]Laboratory of Cancer Genomics and Molecular Pathology. [2]Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. [3]Research Institute of Pharmaceutical Science. [4]Interdiciplinary Program of Bioinformatics, Department of Pharmacy, Seoul National University College of Pharmacy, Seoul, Korea. [5]Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's hospital, Catholic University, Seoul, Korea. [6]Cancer Early Detection Branch, National Cancer Control Research Institute, National Cancer Center, Goyang, Korea. [7]Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. [8]Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. [9]Department of Pathology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea. [10]Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Reference
1. Choi YL, Oh E, Park S, et al: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 10:507.